However, the preliminary results suggest that a majority of RMSs and tumors of fibroblastic origin may overexpress CD117, which indicates the opportunity for TKI-based therapy in dogs with unresectable disease with or without distant metastasis. Here, KIT is linked to Bannayan-Riley-Ruvalcaba syndrome.